mesenchymal stem cells
AssetCell therapyAlso Cellavita HD Lower Dose, Cellavita-HD, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), aMBMC
Umbilical cord-derived mesenchymal stem cells for tissue repair and immunomodulation
- Stage
- Phase 2
- Modality
- Cell therapy
- Target
- Inflammation
- Indications
- 18
- Trials
- 128
- Developers
- 11
Indications
18COVID-19 pneumonia
Phase 2COMPLETEDNCT04361942clinicaltrials.gov7 Oct 2026
Huntington's disease
Phase 2UNKNOWNNCT04219241clinicaltrials.gov7 Oct 2026
Knee arthritis osteoarthritis
Phase 2RECRUITINGNCT07542808clinicaltrials.gov7 Oct 2026
15 more
- Targets and what it contains2
- Owner and partners11
- Trials128
- Evidence for its targets3
- Competitors12
- Aging relevance3
- Signals6
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 26 sources